Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Cor Therapeutics receives nonapprovable letter for Integrilin NDA

March 26, 1997

CPMP approves lepirudin

March 24, 1997

RPR seeks FDA approval for new indications for Lovenox

March 24, 1997

Promising phase II data presented for Novastan in acute MI

March 21, 1997

Fujisawa presents selective, nonpeptide thrombin receptor inhibitor

March 21, 1997

Fujisawa selects orally active fibrinogen antagonist for clinical studies

March 20, 1997

Meiji Seika's new orally active gpIIb/IIIa antagonist

March 20, 1997

Mitsui Toatsu reveals orally active antiplatelet agent

March 20, 1997

InTIME trial indicates nPA superior to tPA in MI

March 19, 1997

Aggrastat prevents heart attack, death and other complications in unstable angina

March 19, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...